Search results
Showing 676 to 690 of 721 results for innovative
NICE's flexibility in evaluation of new health tech and fairer patient access
Changes to the way medicines and other health technologies are evaluated by NICE for use in the NHS were approved by its Board.
Increasing the capacity of our technology appraisals - the proportionate way
Jenniffer Prescott describes how we are trialling a proportionate approach to technology appraisals, which we expect will increase our capacity by 20% from 2023/24.
Working at the forefront of neurodegenerative disease research
Claire Hawksworth reveals NICE’s role in a global partnership to better understand neurodegenerative conditions and speed up delivery of innovative treatments.
Dr Sam Roberts, chief executive of NICE, celebrates the NHS on its 75th anniversary. She discusses how NICE has supported the NHS with its recent achievements. She also highlights how NICE is evolving; through driving value-based healthcare to support the NHS as it adapts to meet current challenges.
Risdiplam not recommend for treating spinal muscular atrophy
NICE has today (2 June 2021) published draft guidance for which does not recommend risdiplam for treating the rare genetic disorder spinal muscular atrophy (SMA).
Over 500 people a year can access a new life extending lung cancer treatment
An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC) in adults is being recommended by NICE as an option for use within the Cancer Drugs Fund.
Two new treatment options for incurable blood cancer assessed
We’ve recommended 2 new treatments for multiple myeloma, an incurable blood cancer that affects bone marrow, in draft guidance issued for public consultation.
More than 20 pieces of draft and final guidance on a range of medicines and medical conditions were published during the pre-election period.
NICE recommends innovative technology for people with breast cancer
A magnetic marker liquid injected into people with invasive breast cancer will help surgeons discover if the cancer has spread.
People in England could benefit from new endometrial cancer treatment
Innovative new drug for treating endometrial cancer in adults recommended by NICE as an option for use within the Cancer Drugs Fund.
NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the new class of Alzheimer’s drugs but key issues need to be considered, a new report has found.
NICE has approved mavacamten, the first treatment that specifically targets a heart condition called obstructive hypertrophic cardiomyopathy (HCM). It means around 7,000 people will now be able to access the treatment on the NHS.
Around 105,000 people with type 1 diabetes could benefit from NICE’s draft recommendation
Around 1,500 people aged 12 years and over with melanoma are set to benefit from pembrolizumab, a drug that reduces the chance of it returning.
Change in treatment for people with early breast cancer to benefit around 4,000
Around 4,000 people are set to benefit from a change in treatment for early breast cancer following provisional approval by NICE of abemaciclib in combination with hormone therapy.